Twist Bioscience Co. (NASDAQ:TWST) Shares Sold by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company trimmed its stake in shares of Twist Bioscience Co. (NASDAQ:TWST) by 3.4% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 30,001 shares of the company’s stock after selling 1,063 shares during the quarter. The Manufacturers Life Insurance Company owned about 0.05% of Twist Bioscience worth $1,355,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Caprock Group LLC lifted its position in Twist Bioscience by 2.9% during the 2nd quarter. Caprock Group LLC now owns 7,851 shares of the company’s stock worth $387,000 after acquiring an additional 220 shares during the period. Signaturefd LLC raised its stake in shares of Twist Bioscience by 63.0% during the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after buying an additional 306 shares in the last quarter. Arizona State Retirement System raised its stake in shares of Twist Bioscience by 1.9% during the 2nd quarter. Arizona State Retirement System now owns 16,187 shares of the company’s stock worth $798,000 after buying an additional 308 shares in the last quarter. Massachusetts Financial Services Co. MA raised its stake in shares of Twist Bioscience by 3.5% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 9,279 shares of the company’s stock worth $457,000 after buying an additional 312 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Twist Bioscience by 21.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock worth $98,000 after buying an additional 381 shares in the last quarter.

Twist Bioscience Stock Performance

NASDAQ:TWST opened at $51.56 on Wednesday. The company has a market capitalization of $3.06 billion, a price-to-earnings ratio of -14.32 and a beta of 1.82. Twist Bioscience Co. has a one year low of $26.51 and a one year high of $60.90. The stock has a 50-day simple moving average of $44.65 and a 200 day simple moving average of $46.58.

Insider Buying and Selling at Twist Bioscience

In related news, SVP Paula Green sold 1,057 shares of the business’s stock in a transaction that occurred on Monday, November 4th. The stock was sold at an average price of $41.56, for a total transaction of $43,928.92. Following the sale, the senior vice president now owns 121,013 shares of the company’s stock, valued at $5,029,300.28. The trade was a 0.87 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Emily M. Leproust sold 2,216 shares of the business’s stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $52.70, for a total value of $116,783.20. Following the sale, the chief executive officer now directly owns 674,718 shares in the company, valued at approximately $35,557,638.60. The trade was a 0.33 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 101,787 shares of company stock worth $4,584,508 over the last ninety days. Company insiders own 3.92% of the company’s stock.

Wall Street Analysts Forecast Growth

TWST has been the subject of a number of analyst reports. Barclays cut their target price on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a research note on Tuesday, November 19th. Evercore ISI increased their target price on Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Leerink Partners raised their price objective on Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research note on Thursday, October 17th. TD Cowen reaffirmed a “buy” rating and issued a $58.00 price objective on shares of Twist Bioscience in a research note on Tuesday, November 26th. Finally, Robert W. Baird raised their price objective on Twist Bioscience from $46.00 to $48.00 and gave the company an “outperform” rating in a research note on Tuesday, November 19th. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $51.00.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.